Skip to main content
SpringerLink
Log in

Diabetes and the Kidney

  • Reference work entry
  • First Online:
Diabetes Complications, Comorbidities and Related Disorders

Part of the book series: Endocrinology ((ENDOCR))

  • 1580 Accesses

Abstract

Diabetic renal disease reppresents the first cause of chronic renal disease in industrialized countries. The incidence in developing countries is also increasing. The natural hystory of renal disease in diabetes was first described in type 1 patients and is carachterized by proteinuria and a declining GFR. Retinal disease is also present. In recent years, the natural hystory of the disease has changed with an high incidence of non proteinuric and non progressing courses of the disease. In recent years, new therapeutic agents have beeen introduced with very promising clinical outcome both for renal disease progression and cardiovascular outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 329.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ACE inhibitor in diabetic nephropathy trialist group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A meta analysis of individual patient data Ann Intern Med. 2001;134:370–9.

    Google Scholar 

  • Adler AI, Stevens RJ, Manley SE, et al. UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.

    Article  Google Scholar 

  • American Diabetes Association. Standards of medical Care in Diabetes-2016: summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4–5.

    Google Scholar 

  • Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. New Engl J Med. 2016;375:2096–8.

    Article  Google Scholar 

  • Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.

    Article  CAS  Google Scholar 

  • Bello AK, Hemmelgarn B, Lloyd A, et al. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6(6):1418–26.

    Article  Google Scholar 

  • Bertani T, Gambara V, Remuzzi G. Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. Diabetologia. 1996;39(12):1625–8.

    Article  CAS  Google Scholar 

  • Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  CAS  Google Scholar 

  • Bruno RM, Salvati A, Barzacchi M, et al. Predictive value of dynamic renal resistive index (DRIN) for renal outcome in type 2 diabetes and essential hypertension: a prospective study. Cardiovasc Diabetol. 2014;14:63.

    Article  Google Scholar 

  • Chen SC, Chang JM, Liu WC, et al. Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Exp Diabetes Res. 2012;2012:789325.

    PubMed  Google Scholar 

  • Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97.

    Article  CAS  Google Scholar 

  • Czock D, Aisenpreis U, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther. 2003;41(10):492–7.

    Article  CAS  Google Scholar 

  • De Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.

    Article  Google Scholar 

  • Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–47.

    Article  CAS  Google Scholar 

  • Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54(1):32–43.

    Article  CAS  Google Scholar 

  • Duckworth WC, Kitabchi AE. Insulin metabolism and degradation. Endocr Rev. 1981;2(2):210–33.

    Article  CAS  Google Scholar 

  • Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69(2):375–82.

    Article  CAS  Google Scholar 

  • Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1569–76.

    Article  CAS  Google Scholar 

  • Fioretto P, Steffes MW, Barbosa J, et al. Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes. 1999;48:865–9.

    Article  CAS  Google Scholar 

  • Gall MA, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783–8.

    Article  CAS  Google Scholar 

  • Giorgino F, Laviola L, Cavallo Perin P, et al. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB prospective complications study. Diabetologia. 2004;47:1020–8.

    Article  CAS  Google Scholar 

  • Gnudi L, Karalliedde J. Beat it early. Putative renoprotective hemodynamic effects of oral hypoglicemic agents. Nephrol Dial Transplant. 2016;31:1036–43.

    Article  CAS  Google Scholar 

  • Groop PH, Cooper ME, Perkovic V, et al. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: rationale and design of the MARLINA-T2Dâ„¢ trial. Diab Vasc Dis Res. 2015;12(6):455–62.

    Article  CAS  Google Scholar 

  • Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.

    Article  CAS  Google Scholar 

  • Hasslacher C, Kulozik F, Lorenzo Bermejo J. Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in type 1 diabetic patients with impaired kidney function. Ther Adv Endocrinol Metab. 2016;7(4):166–77.

    Article  CAS  Google Scholar 

  • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.

    Article  Google Scholar 

  • Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60(5):469–76.

    Article  CAS  Google Scholar 

  • Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point? Diabetologia. 2005;48:2454–9.

    Article  CAS  Google Scholar 

  • Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamic in experimental diabetes mellitus. Kidney Int. 1981;19:410–5.

    Article  CAS  Google Scholar 

  • Howse PM, Chibrikova LN, Twells LK et al. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and Meta-analysis. Am J Kidney Dis. 2016. pii: S0272-6386(16)30285-2.

    Google Scholar 

  • Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012;81:698–706.

    Article  CAS  Google Scholar 

  • Kainz A, Hronsky M, Stel VS, et al. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2015. Nephrol Dial Transpl. 2015;30:13–118.

    Article  Google Scholar 

  • KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(s2):S12–S154.

    Google Scholar 

  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;S3:1–150.

    Google Scholar 

  • Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175–83.

    Article  CAS  Google Scholar 

  • Kohan DE, Fioretto P, Tang W, List JF. Long- term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.

    Article  CAS  Google Scholar 

  • Kramer H, Toto R, Peshock R, et al. Association between chronic kidney disease and coronary artery calcification: the Dallas heart study. J Am Soc Nephrol. 2005;16(2):507–13.

    Article  Google Scholar 

  • Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113–21.

    Article  CAS  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. For the collaborative study group*. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.

    Article  CAS  Google Scholar 

  • Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.

    Article  CAS  Google Scholar 

  • MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care. 2006;29(7):1560–6.

    Article  Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016a;375(4):311–22.

    Article  CAS  Google Scholar 

  • Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (trial comparing cardiovascular safety of insulin Degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events) – DEVOTE 1. Am Heart J. 2016b;179:175–83.

    Article  CAS  Google Scholar 

  • Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.

    Article  Google Scholar 

  • Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–7.

    Article  CAS  Google Scholar 

  • Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42:263–85.

    Article  CAS  Google Scholar 

  • Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from kidney disease: improving global outcomes. Kidney Int. 2015;87:20–30.

    Article  Google Scholar 

  • Moody WE, Edwards NC, Chue CD, et al. Townend arterial disease in chronic kidney disease. Heart. 2013;99(6):365–72.

    Article  CAS  Google Scholar 

  • Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2010;55(1):21–30.

    Article  Google Scholar 

  • Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012;59(1):75–83.

    Article  Google Scholar 

  • Papadopoulou-Marketou NP, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis and diagnosis. Diabetes Metab Res Rev. 2016. [Epub ahead of print].

    Google Scholar 

  • Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.

    Article  CAS  Google Scholar 

  • Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of Aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.

    Article  CAS  Google Scholar 

  • Penno G, Solini A, Bonora E, the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29:1802–9.

    Article  CAS  Google Scholar 

  • Penno G, Solini A, Zoppini G, Renal Insufficiency And Cardiovascular Events (RIACE) Study Group, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012;35(11):2317–23.

    Article  CAS  Google Scholar 

  • Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–29.

    Article  CAS  Google Scholar 

  • Ragot S, Saulnier PJ, Velho G, Gand E, et al. Dynamic changes in renal function are associated with major cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2016;39(7):1259–66.

    Article  CAS  Google Scholar 

  • Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, the UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55:1832–9.

    Article  CAS  Google Scholar 

  • Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601–10.

    Article  Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941–51.

    Article  CAS  Google Scholar 

  • Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–8.

    Article  CAS  Google Scholar 

  • Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res. 2014;11(5):306–23.

    Article  CAS  Google Scholar 

  • Shilpak M. Diabetic nephropathy: preventing progression. BMJ. 2010.

    Google Scholar 

  • Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17(5):365–70.

    Article  Google Scholar 

  • Solini A, Penno G, Bonora E, Renal Insufficiency And Cardiovascular Events (RIACE) Study Group, et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012;35(1):143–9.

    Article  CAS  Google Scholar 

  • Solini A, Zoppini G, Orsi E, et al. Renal insufficiency and cardiovascular events (RIACE) study group. Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. J Hypertens. 2014;32(12):2401–10.

    Article  CAS  Google Scholar 

  • Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in type 1 diabetes. III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes. 2005;54:2164–71.

    Article  CAS  Google Scholar 

  • Tabaei BP, Al-Kassab AS, Ilag LL, et al. Does microalbuminuria predict diabetic nephropathy? Diabetes Care. 2001;24:1560–6.

    Article  CAS  Google Scholar 

  • Tanaka T, Higashijima Y, Wada T, et al. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86(4):701–11.

    Article  CAS  Google Scholar 

  • The 2016 USA Annual Renal data System. https://www.usrds.org/adr.aspx

  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

    Article  Google Scholar 

  • Tonelli M, Muntner P, Lloyd A, Alberta Kidney Disease Network, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14.

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  • Urata H, Mori K, Emoto M, et al. Advantage of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal insufficiency. J Ren Nutr. 2015;25(2):129–34.

    Article  CAS  Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:1799–800.

    Article  Google Scholar 

  • Yale JF, Bakris G, Cariou B, et al. DIA3004 study group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–27.

    Article  CAS  Google Scholar 

  • Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925–30.

    Article  CAS  Google Scholar 

  • Zoungas S, Chalmers J, Neal B, ADVANCE- ON Collaborative Group, et al. Follow-up of blood- pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392–406.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy

    Anna Solini

  2. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

    Pietro Castellino

Authors
  1. Anna Solini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pietro Castellino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Solini .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy

    Enzo Bonora

  2. Diabetes Division, Diabetes Research Unit, University of Texas Health Science Center, San Antonio, TX, USA

    Ralph A. DeFronzo

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Solini, A., Castellino, P. (2018). Diabetes and the Kidney. In: Bonora, E., DeFronzo, R. (eds) Diabetes Complications, Comorbidities and Related Disorders. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44433-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44433-8_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44432-1

  • Online ISBN: 978-3-319-44433-8

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation